NCT03522441View on ClinicalTrials.gov

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

PHASE3CompletedINTERVENTIONAL
Enrollment

1,125

Participants

Timeline

Start Date

April 27, 2018

Primary Completion Date

April 22, 2019

Study Completion Date

April 22, 2019

Conditions
Acne Vulgaris
Interventions
DRUG

Clindamycin 1% Gel

Topical gel

DRUG

Placebo

Topical Placebo gel

Trial Locations (12)

27262

Site 12, High Point

33027

Site 4, Miramar

Site 5, Miramar

33069

Site 2, Tampa

33511

Site 1, Brandon

33618

Site 3, Tampa

79902

Site 8, El Paso

79925

Site 9, El Paso

91403

Site 10, Sherman Oaks

91436

Site 11, Encino

Unknown

Site 6, Belize City

Site 7, Belize City

All Listed Sponsors
lead

Akorn, Inc.

INDUSTRY

NCT03522441 - Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris | Biotech Hunter | Biotech Hunter